BioCentury | Oct 21, 2020
Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

...research administration and industry relations at the University of Texas MD Anderson Cancer Center.Examples...
...remains managing partner of Louisiana-based BVM Capital. Paul Bonanos University of Texas MD Anderson Cancer Center...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...NASDAQ:ALLO) entered a five-year collaboration with The University of Texas MD Anderson Cancer Center...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...fusion inhibitors is a plus for patients, University of Texas MD Anderson Cancer Center’s...
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...Francisco, Memorial Sloan Kettering Cancer Center and University of Texas MD Anderson Cancer Center...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...to run biomarker based cancer trials Sanofi (Euronext:SAN; NASDAQ:SNY) announced a five-year collaboration with the University of Texas MD Anderson Cancer Center...
...Brand), FX006 (Compound #), Sustained-release triamcinolone acetonide (Generic), triamcinolone acetonide extended-release injectable suspension (Informal), Zilretta (Other) Sanofi University of Texas MD Anderson Cancer Center Cytokinetics...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...board. Allison is professor and chair of immunology and executive director of immunotherapy at the University of Texas MD Anderson Cancer Center...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

...and fewer safety risks. Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center...
...of patients was small, efficacy signals from a CD19-targeted CAR NK cell therapy from The University of Texas MD Anderson Cancer Center...
...cell death 1 ligand 1 TCR - T cell receptor Lauren Martz, Senior Editor Takeda Pharmaceutical Co. Ltd. University of Texas MD Anderson Cancer Center CD19...
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...manufacturing as very important.” Rick Fair, Bellicum On Tuesday, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Deerfield Management Bio-Techne Corp. Fresenius SE & Co. KGaA Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Nationwide...
BioCentury | Jan 22, 2020
Company News

JV to combine technologies into one gene and cell therapy manufacturing platform

...of lower doses (see "Gene Therapy 2.0" ). Separately, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Programmed cell death 1 TGF-β - Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Fresenius...
BioCentury | Jan 13, 2020
Politics & Policy

Academic sponsors lag industry in reporting clinical trial results

...Medicine as “habitual violators” of reporting requirements. Other institutions with poor track records include the University of Texas MD Anderson Cancer Center...
Items per page:
1 - 10 of 435
BioCentury | Oct 21, 2020
Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

...research administration and industry relations at the University of Texas MD Anderson Cancer Center.Examples...
...remains managing partner of Louisiana-based BVM Capital. Paul Bonanos University of Texas MD Anderson Cancer Center...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...NASDAQ:ALLO) entered a five-year collaboration with The University of Texas MD Anderson Cancer Center...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

...fusion inhibitors is a plus for patients, University of Texas MD Anderson Cancer Center’s...
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...Francisco, Memorial Sloan Kettering Cancer Center and University of Texas MD Anderson Cancer Center...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

...to run biomarker based cancer trials Sanofi (Euronext:SAN; NASDAQ:SNY) announced a five-year collaboration with the University of Texas MD Anderson Cancer Center...
...Brand), FX006 (Compound #), Sustained-release triamcinolone acetonide (Generic), triamcinolone acetonide extended-release injectable suspension (Informal), Zilretta (Other) Sanofi University of Texas MD Anderson Cancer Center Cytokinetics...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

...board. Allison is professor and chair of immunology and executive director of immunotherapy at the University of Texas MD Anderson Cancer Center...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

...and fewer safety risks. Though the data come from only 11 patients, a study from University of Texas MD Anderson Cancer Center...
...of patients was small, efficacy signals from a CD19-targeted CAR NK cell therapy from The University of Texas MD Anderson Cancer Center...
...cell death 1 ligand 1 TCR - T cell receptor Lauren Martz, Senior Editor Takeda Pharmaceutical Co. Ltd. University of Texas MD Anderson Cancer Center CD19...
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...manufacturing as very important.” Rick Fair, Bellicum On Tuesday, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Deerfield Management Bio-Techne Corp. Fresenius SE & Co. KGaA Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Nationwide...
BioCentury | Jan 22, 2020
Company News

JV to combine technologies into one gene and cell therapy manufacturing platform

...of lower doses (see "Gene Therapy 2.0" ). Separately, Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) said the University of Texas MD Anderson Cancer Center...
...Programmed cell death 1 TGF-β - Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Fresenius...
BioCentury | Jan 13, 2020
Politics & Policy

Academic sponsors lag industry in reporting clinical trial results

...Medicine as “habitual violators” of reporting requirements. Other institutions with poor track records include the University of Texas MD Anderson Cancer Center...
Items per page:
1 - 10 of 435